Ligand Pharmaceuticals (LGND) EBIT Margin (2010 - 2026)
Ligand Pharmaceuticals (LGND) reported EBIT Margin of 33.58% for Q1 2026, up 11347.0% on a YoY basis from N/an in Q1 2025, and up 44.73% sequentially from 23.2% in Q4 2025.
Ligand Pharmaceuticals (LGND) EBIT Margin (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 17 years of EBIT Margin data on file, last reported at 33.58% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin rose 11347.0% year-over-year to 33.58%; the trailing twelve-month figure through Mar 2026 stood at 34.46% (up 6852.0% YoY), and the FY2025 full-year result was 15.29%, up 2882.0% from the prior year.
- EBIT Margin improved to 33.58% in Q1 2026, from 23.2% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 47.58% in Q3 2025 to a low of 79.89% in Q1 2025.
- A 5-year average of 0.92% and a median of 9.36% in 2023 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin sank 10671 bps in 2022 and soared 11347 bps in 2026, its largest moves.
- Tracing LGND's EBIT Margin over 5 years: stood at 39.89% in 2022, then soared by 70 bps to 11.95% in 2023, then sank by 88 bps to 22.51% in 2024, then surged by 203 bps to 23.2% in 2025, then soared by 45 bps to 33.58% in 2026.
- Business Quant data shows LGND's EBIT Margin at 33.58% in Q1 2026, 23.2% in Q4 2025, and 47.58% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | 33.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.58% |
| Dec 31, 2025 | 23.20% |
| Sep 30, 2025 | 47.58% |
| Jun 30, 2025 | 17.73% |
| Mar 31, 2025 | -79.89% |
| Dec 31, 2024 | -22.51% |
| Sep 30, 2024 | 6.07% |
| Jun 30, 2024 | -45.99% |
| Mar 31, 2024 | 9.65% |
| Dec 31, 2023 | -11.95% |
| Sep 30, 2023 | 9.36% |
| Jun 30, 2023 | -7.52% |
| Mar 31, 2023 | 32.30% |
| Dec 31, 2022 | -39.89% |
| Sep 30, 2022 | 20.84% |
| Jun 30, 2022 | 17.28% |
| Mar 31, 2022 | 5.84% |
| Dec 31, 2021 | 66.82% |
| Sep 30, 2021 | 26.31% |
| Jun 30, 2021 | 58.00% |